Brunhilde Schweiger

Brunhilde Schweiger

Auto-generated profile, based on publicly available information

Brunhilde Schweiger

Unit 17, Influenza and Other Respiratory Viruses, Department of Infectious Diseases, National Influenza Centre Robert Koch Institute Berlin Germany

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2018 in Reviews in Medical Virology
Verified
Journal Article
Closed access
PDF file
XMXiaolin Ma
Xiaolin Ma
TCTim OF Conrad
Tim OF Conrad
MAMaren Alchikh
Maren Alchikh
JRJanine Reiche
Janine Reiche
BSBrunhilde Schweiger
Brunhilde Schweiger
BRBarbara A Rath
Barbara A Rath

12 May 2017 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
BRBarbara A Rath
Barbara A Rath
TCTim OF Conrad
Tim OF Conrad
PMPuja Myles
Puja Myles
MAMaren Alchikh
Maren Alchikh
XMXiaolin Ma
Xiaolin Ma
BSBrunhilde Schweiger
Brunhilde Schweiger
Influenza-Like Illness is a leading cause of hospitalization in children. Disease burden due to influenza and other respiratory viral infections is reported on a population level, but clinical scores measuring individual changes in disease severity are urgently needed. Areas covered: We present a composite clinical score allowing individual patient data analyses of disease severity based on systematic literature review and WHO-criteria for uncomplicated and complicated disease. The 22-item ViVI Disease Severity Score showed a normal distribution in a pediatric cohort of 6073 children aged 0-18 years (mean age 3.13; S.D. 3.89; range: 0 to 18.79). Expert commentary: The ViVI Score was correlated with risk of antibiotic use as well as need for hospitalization and intensive care. The ViVI Score was used to track children with influenza, respiratory syncytial virus, human metapneumovirus, human rhinovirus, and adenovirus infections and is fully compliant with regulatory data standards. The ViVI Disease Severity Score mobile application allows physicians to measure disease severity at the point-of care thereby taking clinical trials to the next level.

28 March 2024 in Eurosurveillance
Verified
Journal Article
Open access
WCWei Cai
Wei Cai
SKSophie Köndgen
Sophie Köndgen
KTKristin Tolksdorf
Kristin Tolksdorf
RDRalf Dürrwald
Ralf Dürrwald
ESEkkehard Schuler
Ekkehard Schuler
JRJanine Reiche
Janine Reiche
Background: Non-pharmaceutical interventions (NPIs) during the COVID-19 pandemic affected respiratory syncytial virus (RSV) circulation worldwide. Aim: To describe, for children aged < 5 years, the 2021 and 2022/23 RSV seasons in Germany. Methods: Through data and 16,754 specimens from outpatient sentinel surveillance, we investigated RSV seasonality, circulating lineages, and affected children’s age distributions in 2021 and 2022/23. Available information about disease severity from hospital surveillance was analysed for patients with RSV-specific diagnosis codes (n = 13,104). Differences between RSV seasons were assessed by chi-squared test and age distributions trends by Mann–Kendall test. Results: RSV seasonality was irregular in 2021 (weeks 35–50) and 2022/23 (weeks 41–3) compared to pre-COVID-19 2011/12–2019/20 seasons (median weeks 51–12). RSV positivity rates (RSV-PR) were higher in 2021 (40% (522/1,291); p < 0.001) and 2022/23 (30% (299/990); p = 0.005) than in prior seasons (26% (1,430/5,511)). Known globally circulating RSV-A (lineages GA2.3.5 and GA2.3.6b) and RSV-B (lineage GB5.0.5a) strains, respectively, dominated in 2021 and 2022/23. In 2021, RSV-PRs were similar in 1 – < 2, 2 – < 3, 3 – < 4, and 4 – < 5-year-olds. RSV hospitalisation incidence in 2021 (1,114/100,000, p < 0.001) and in 2022/23 (1,034/100,000, p < 0.001) was approximately double that of previous seasons’ average (2014/15–2019/20: 584/100,000). In 2022/23, proportions of RSV patients admitted to intensive care units rose (8.5% (206/2,413)) relative to pre-COVID-19 seasons (6.8% (551/8,114); p = 0.004), as did those needing ventilator support (6.1% (146/2,413) vs 3.8% (310/8,114); p < 0.001). Conclusions: High RSV-infection risk in 2–4-year-olds in 2021 and increased disease severity in 2022/23 possibly result from lower baseline population immunity, after NPIs diminished exposure to RSV.

29 April 2022 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
WCWei Cai
Wei Cai
RDRalf Dürrwald
Ralf Dürrwald
BBBarbara Biere
Barbara Biere
BSBrunhilde Schweiger
Brunhilde Schweiger
WHWalter Haas
Walter Haas
JRJanine Reiche
Janine Reiche
Based on our national outpatient sentinel surveillance, we have developed a novel approach to determine respiratory syncytial virus (RSV) epidemic seasons in Germany by using RSV positivity rate and its lower limit of 95% confidence interval. This method was evaluated retrospectively on nine RSV seasons, and it is also well‐suited to describe off‐season circulation of RSV in near real time as observed for seasons 2020/21 and 2021/22 during the COVID‐19 pandemic. Prospective application is of crucial importance to enable timely actions for health service delivery and prevention.

6 June 2019 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
PDF file
BRBarbara A Rath
Barbara A Rath
Helena MaltezouHelena Maltezou
Helena Maltezou
VPVassiliki Papaevangelou
Vassiliki Papaevangelou
MPMaria‐Alexandra Papagrigoriou‐Theodoridou
Maria‐Alexandra Papagrigoriou‐Theodoridou
MAMaren Alchikh
Maren Alchikh
TNThe Pedsidea Network
The Pedsidea Network
Background: Standardised clinical outcome measures are urgently needed for the surveillance of influenza and influenza‐like illness (ILI) based on individual patient data (IPD).Objectives: We report a multicentre prospective cohort using a predefined disease severity score in routine care.Patients/Methods: The Vienna Vaccine Safety initiative (ViVI) Disease Severity Score (“ViVI Score”) was made available as an android‐based mobile application to three paediatric hospitals in Berlin and Athens between 2013 and 2016. Healthcare professionals assessed ILI patients at the point of care including severity, risk factors and use of antibiotics/antivirals/vaccines. RT‐PCR for influenza A/B viruses was performed at the Hellenic Pasteur Institute and the Robert Koch Institute. PCR testing was blinded to severity scoring and vice versa.Results: A total of 1615 children aged 0‐5 years (54.4% males) were assessed at the three sites. The mean age was 1.7 years (SD 1.5; range 0‐5.9). The success rate (completion of the scoring without disruption to the ER workflow) was 100%. ViVI Disease Severity Scores ranged from 0 to 35 (mean 13.72). Disease severity in the Berlin Cohort was slightly higher (mean 15.26) compared to the Athens Cohorts (mean 10.86 and 11.13). The administration of antibiotics was most prevalent in the Berlin Cohort, with 41.2% on antibiotics (predominantly cefuroxime) as opposed to only 0.5% on neuraminidase inhibitors. Overall, Risk‐adjusted ViVI Scores were significantly linked to the prescription of both, antibiotics and antivirals.Conclusions: The Risk‐adjusted ViVI Score enables a precision medicine approach to managing ILI in multicentre settings. Using mobile applications, severity data will be obtained in real time with important implications for the evaluation of antiviral/vaccine use.

18 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SDSusanne Caroline Duwe
Susanne Caroline Duwe
JMJeanette Milde
Jeanette Milde
AHAlla Heider
Alla Heider
MWMarianne Wedde
Marianne Wedde
BSBrunhilde Schweiger
Brunhilde Schweiger
RDRalf Dürrwald
Ralf Dürrwald
Background The unexpected emergence of oseltamivir-resistant A(H1N1) viruses in 2008 was facilitated in part by the establishment of permissive secondary neuraminidase (NA) substitutions that compensated for the fitness loss due to the NA-H275Y resistance substitution. These viruses were replaced in 2009 by oseltamivir-susceptible A(H1N1)pdm09 influenza viruses. Methods Genetic analysis and screening A(H1N1)pdm09 viruses circulating in Germany between 2009 and 2024 were conducted to identify any potentially permissive or resistance-associated NA substitutions. Selected viruses were then subjected to further characterization in vitro. Results In the NA gene of circulating A(H1N1)pdm09 viruses, two secondary permissive substitutions, NA-V241I and NA-N369K, were identified. These substitutions demonstrated a stable lineage in phylogenetic analysis since the 2010-2011 influenza season. The data indicates a slight increase in viral NA bearing two additional potentially permissive substitutions, NA-I223V and NA-S247N, in the 2023-2024 season, that both result in a slight reduction in susceptibility to NA inhibitors. Conclusions The accumulation of secondary permissive substitutions in the NA of A(H1N1)pdm09 viruses increases the probability of the emergence of antiviral-resistant viruses. Therefore, it is crucial to closely monitor the evolution of circulating influenza viruses and to develop additional antiviral drugs against different target proteins.